Patents by Inventor David Norman Deaton

David Norman Deaton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical Compounds
    Publication number: 20220009918
    Abstract: A compound of formula (I), wherein Ar1, R21, R23, R24, R25, R26, R27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: November 6, 2019
    Publication date: January 13, 2022
    Inventors: Rodolfo Cadilla, David Norman Deaton, Andrew L. Larkin, Christie Schulte, Terrence L. Smalley
  • Chemical compounds as H—PGDS inhibitors
    Patent number: 11149035
    Abstract: A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: October 19, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED
    Inventors: David Norman Deaton, Barry George Shearer, Mark Andrew Youngman
  • CHEMICAL COMPOUNDS
    Publication number: 20210238162
    Abstract: The present invention relates to compounds of Formula (XI): wherein R1a, R2a, R3a, R4a, R5a, R6a, and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) inhibitors and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: December 15, 2016
    Publication date: August 5, 2021
    Inventors: Rodolfo CADILLA, David Norman DEATON, Ashley Paul HANCOCK, Heather HOBBS, Simon Teanby HODGSON, Andrew L. LARKIN, Joelle LE, Paul N. MORTENSON, Daniel J. PRICE, Gordon SAXTY, Lee T. SCHALLER, Christie SCHULTE, Ian Edward David SMITH, Stephen Andrew THOMSON, Joseph Wendell WILSON
  • 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
    Patent number: 11053234
    Abstract: A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: July 6, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: David Norman Deaton, Yu Guo, Ashley Paul Hancock, Christie Schulte, Barry George Shearer, Emilie Despagnet Smith, Eugene L. Stewart, Stephen Andrew Thomson
  • FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS
    Publication number: 20210139507
    Abstract: A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: December 12, 2018
    Publication date: May 13, 2021
    Inventors: David Norman DEATON, Rodolfo CADILLA
  • Chemical Compounds as H-PGDS Inhibitors
    Publication number: 20200123152
    Abstract: A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: June 11, 2018
    Publication date: April 23, 2020
    Inventors: David Norman DEATON, Barry George SHEARER, Mark Andrew YOUNGMAN
  • 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS
    Publication number: 20190241554
    Abstract: A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: October 12, 2017
    Publication date: August 8, 2019
    Inventors: David Norman DEATON, Yu GUO, Ashley Paul HANCOCK, Christie SCHULTE, Barry George SHEARER, Emilie Despagnet SMITH, Eugene L. STEWART, Stephen Andrew THOMSON
  • CD38 inhibitors and methods of treatment
    Patent number: 9840496
    Abstract: Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: December 12, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: J. David Becherer, Rodolfo Cadilla, David Norman Deaton, Curt Haffner, Brad Richard Henke, Frank Preugschat, Christie Schulte
  • CD38 INHIBITORS AND METHODS OF TREATMENT
    Publication number: 20170260164
    Abstract: Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: September 14, 2017
    Inventors: J. David BECHERER, Rodolfo CADILLA, David Norman DEATON, Curt HAFFNER, Brad Richard HENKE, Frank PREUGSCHAT, Christie SCHULTE
  • Farnesoid X receptor agonists
    Patent number: 8158665
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: April 17, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Richard Caldwell, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • Farnesoid X receptor agonists
    Patent number: 7960552
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: June 14, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Jonathan York Bass, III, Justin Caravella, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • FARNESOID X RECEPTOR AGONISTS
    Publication number: 20110034507
    Abstract: The present invention relates to farnesoid X receptors (FXR, NR1H4). FXR is a member of the nuclear receptor class of ligand-activate transcription factors. More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same. Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome.
    Type: Application
    Filed: June 13, 2008
    Publication date: February 10, 2011
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Adwoa Akwabi-Ameyaw, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III
  • Farnesoid X Receptor Agonists
    Publication number: 20100249179
    Abstract: The present invention provides novel isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: June 13, 2008
    Publication date: September 30, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: David Norman Deaton, Frank Navas, III, Paul Kenneth Spearing
  • Farnesoid X Receptor Agonists
    Publication number: 20100160398
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: March 9, 2010
    Publication date: June 24, 2010
    Inventors: Richard Caldwell, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • Farnesoid X Receptor Agonists
    Publication number: 20100120775
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: October 23, 2007
    Publication date: May 13, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Jonathan York Bass, III, David Norman Deaton, Justin Caravella, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
  • Farnesoid X receptor agonists
    Patent number: 7705028
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: April 27, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Richard Caldwell, David Norman Deaton, Robert Blout McFayden, Frank Navas, III, Paul Kenneth Spearing
  • Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss
    Patent number: 7402606
    Abstract: Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: July 22, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: David Gene Barrett, John G. Catalano, David Norman Deaton, Aaron Bayne Miller, John A. Ray, Vicente Samano
  • FARNESOID X RECEPTOR AGONISTS
    Publication number: 20080167356
    Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: December 13, 2006
    Publication date: July 10, 2008
    Applicant: SmithKline Beecham Corporation
    Inventors: Richard CALDWELL, David Norman Deaton, Robert Blount McFayden, Frank Navas, Paul Kenneth Spearing
  • Propylcarbamate derivatives as inhibitors of serine and cysteine proteases
    Patent number: 7288541
    Abstract: The present invention includes ketone derivatives (I) and (II), which are useful as cathepsin K inhibitors.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: October 30, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: David Norman Deaton, John George Catalano
  • Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
    Patent number: 7282512
    Abstract: Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: October 16, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: John George Catalano, David Norman Deaton, Aaron Bayne Miller, Francis Xavier Tavares